Core Viewpoint - The resignation of Chairman Hu Yonggang due to age raises concerns about how the new leadership will maintain the company's technological edge and reverse declining performance in the pharmaceutical glass industry [1][2]. Group 1: Leadership Changes - Hu Yonggang has resigned from all positions including Chairman, Director, and various committee roles, effective immediately [1]. - Zhang Jun, a long-time employee of the company, has been appointed to act as Chairman until a new Chairman is elected [2]. Group 2: Financial Performance - In the first three quarters of 2025, the company reported a net profit attributable to shareholders of 6.48 billion yuan, a significant decline of 25.66% year-on-year [3]. - Revenue for the first nine months of 2025 was 34.01 billion yuan, down 11.10% compared to the previous year, with third-quarter revenue at 10.27 billion yuan, reflecting a 17.14% decrease [3][4]. - Despite the decline in revenue and profit, the company distributed a cash dividend of 2.80 yuan per 10 shares in the first half of 2025, totaling 1.86 billion yuan [4]. Group 3: Product Performance - The company remains a leader in the domestic pharmaceutical packaging materials sector, with core products like molded bottles and brown bottles showing continued sales growth [3]. - For the fiscal year 2024, the company reported total revenue of 51.25 billion yuan, with molded bottles contributing 23.53 billion yuan and a gross margin of 43.26% [3].